

1 ***Mettl14* is required for mouse post-implantation development by**
2 **facilitating epiblast maturation**

3 Tie-Gang Meng^{1,2,*}, Xukun Lu^{1,2,*}, Lei Guo^{1,3,*}, Guan-Mei Hou¹, Xue-Shan Ma¹, Qian-Nan Li¹, Lin Huang¹,
4 Li-Hua Fan^{1,2}, Zheng-Hui Zhao^{1,2}, Xiang-Hong Ou³, Ying-Chun OuYang¹, Heide Schatten⁴, Lei Li^{1,2}, Zhen-Bo
5 Wang^{1,2,#} and Qing-Yuan Sun^{1,2,#}

6
7 ¹State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of
8 Sciences, Beijing 100101, China;

9 ²University of Chinese Academy of Sciences, Beijing 100101, China;

10 ³Fertility Preservation Lab, Reproductive Medicine Center, Guangdong Second Provincial General Hospital,
11 Guangzhou 510317, China

12 ⁴Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA

13 *These authors contributed equally to this work.

14 Short title: *Mettl14* facilitating epiblast maturation

15 #Correspondence to: Qing-Yuan Sun, State Key Laboratory of Stem Cell and Reproductive Biology, Institute of
16 Zoology, Chinese Academy of Sciences, #1 Beichen West Rd, Chaoyang, Beijing 100101, China;
17 Tel./Fax:86-10-64807050; Email: sunqy@ioz.ac.cn; or Zhen-Bo Wang, State Key Laboratory of Stem Cell and
18 Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, #1 Beichen West Rd, Chaoyang,
19 Beijing100101, China; Tel.:86-10-64807090; Email: wangzb@ioz.ac.cn.

20
21 **ABSTRACT**

22 N6-methyladenosine (m⁶A) is the most prevalent and reversible internal modification of mammalian messenger

23 and noncoding RNAs mediated by specific m⁶A writer, reader, and eraser proteins. As an m⁶A writer, the
24 METTL3–METTL14-WTAP complex dynamically regulates m⁶A modification and plays important roles in
25 diverse biological processes. However, our knowledge about the complete functions of this RNA
26 methyltransferase complex, the contributions of each component to the methylation and their impacts on
27 different biological pathways, are still very limited. Here, by employing both *in vivo* and *in vitro* models, we
28 report that METTL14 was indispensable for post-implantation embryonic development by facilitating the
29 conversion from naïve to primed state of the epiblast. Depletion of *Mettl14* lead to conspicuous embryonic
30 growth retardation from E6.5 mainly as a result of resistance to differentiation, which further lead to embryonic
31 lethality early in gestation. Our data highlight the critical function of METTL14, as an m⁶A modification regulator,
32 in orchestrating early mouse embryogenesis.

33 **Key words**

34 N6-methyladenosine, *Mettl14*, embryogenesis, naïve state, primed state, gene expression

35

36 **INTRODUCTION**

37 Akin to the roles of DNA methylation and histone modifications in epigenetics, N6-methyl-adenosine (m⁶A)
38 is the most abundant internal modification of mRNAs in eukaryotes, and dysregulation of this modification has
39 already been clearly linked to many human diseases, such as obesity, cancer and intellectual disability (Sibbritt
40 et al., 2013). Importantly, since fat-mass and obesity-associated protein (FTO) and ALKBH5 have been shown
41 to act as m⁶A demethylases, it is commonly accepted that m⁶A modifications are reversible in mammalian cells
42 (Jia et al., 2011; Zheng et al., 2013), evoking the biological implications of the dynamic m⁶A modification, which
43 is incompletely understood in mammals.

44 m⁶A formation is catalyzed by the RNA methyltransferase complex containing methyltransferase like 3
45 (METTL3), methyltransferase like 14 (METTL14) and Wilms' tumor 1-associating protein (WTAP), the writer of
46 the m⁶A marks(Wang et al., 2014). It is interesting and fascinating that the RNA methyltransferase complex
47 contains two methyltransferase subunits, which could catalyze m⁶A formation, respectively. Furthermore, it
48 appears that METTL3 and METTL14 impact different targets, in spite of a common set of substrates (Liu et al.,
49 2014). Contributions from each component to the methylation and their impacts on different biological
50 pathways are unclear. METTL3 is the first reported mammalian m⁶A methyltransferase. *Mettl3*-null mutant

51 embryos died by embryonic day 6.5 (E6.5) as a result of failure to down-regulate *Nanog* mRNA level (Geula et
52 al., 2015). However, the function of METTL14 in mammalian development is largely unclear.

53 Early embryonic development in mammals involves a coordinated cell lineage specification from the
54 pluripotent epiblast to diverse types of cells around implantation, which lays the foundation for a successful
55 body plan (Arnold and Robertson, 2009). During this process, naïve pluripotency markers (*Nanog*, *Esrrb*,
56 *Nr5a2*, *Klf2*, *Klf4*, *Rex1*) are down-regulated, and primed pluripotency markers (*Fgf5*, *Otx2*, *Sox3*, *Dnmt3b*,
57 *Wnt3*) are up-regulated, enabling the conversion of the pluripotent epiblast from the naïve to primed state
58 (Kalkan et al., 2017), a process commonly known as epiblast maturation. This conversion is developmentally
59 essential, failure of which would result in early embryonic lethality (Geula et al., 2015; Huang et al., 2017). *In*
60 *vitro* models, including embryonic stem cells (ESCs) (Evans and Kaufman, 1981; Martin, 1981), epiblast-like
61 cells (EpiLCs) (Hayashi et al., 2011) and epiblast stem cells (EpiSCs) (Brons et al., 2007; Tesar et al., 2007)
62 that represent different states of pluripotency *in vivo* have provided many insights into the molecular regulation
63 of the process. However, due to the limitation of materials, techniques and inaccessibility to the process *in vivo*,
64 what we know about epiblast maturation and mammalian early embryogenesis is still very limited.

65 The aim of our present study was to determine the function of METTL14 during embryo development. We
66 deleted *Mettl14* gene using the CRISPR/cas9 system. We found that depletion of *Mettl14* render mouse naïve
67 epiblast or embryonic stem cells resistant to differentiation, leading to embryonic lethality by E6.5.

68

69 RESULTS

70 Establishment of a *Mettl14* knockout mouse model

71 To investigate the physiological function of *Mettl14*, we established a line of *Mettl14* knockout mice using
72 the CRISPR/Cas9 system. Oligos encoding sgRNA that targets the exon2 of *Mettl14* were inserted into px330
73 plasmid. Unique sgRNA sequences were chosen based on the Genetic Perturbation Platform from the Broad
74 Institute website (Cong et al., 2013). We constructed a *Mettl14* targeting vector and microinjected it with Cas9
75 mRNA and gRNA into zygotes of C57BL/6 mice. The sgRNA was designed to target the exon 2 of the
76 endogenous mouse *Mettl14* gene. Six *Mettl14*^{+/-} mice were obtained from these experiments. The genotype of
77 mice including *Mettl14*^{+/+} and *Mettl14*^{+/-} were confirmed by DNA sequencing and nucleic acid electrophoresis

78 (Fig. 1).

79 Thus, we successfully established a *Mettl14* knockout mouse model, which could be used for further
80 phenotypic and functional analysis.

81 **METTL14 is required for mouse early development**

82 Genotyping of postnatal offspring by PCR analysis from *Mettl14* heterozygous intercrosses revealed the
83 absence of mouse homozygous for the *Mettl14* mutation, indicating possible embryonic lethality of *Mettl14*
84 knockout mice early during gestation. In order to determine when the *Mettl14* mutation produced a lethal
85 phenotype, embryos of heterozygous intercrosses were obtained from E3.5-E12.5 (Fig. 2A). Genotyping of
86 these embryos by PCR analysis revealed that *Mettl14* knockout embryos were observed at Mendelian ratios
87 until E6.5, but no mutants were identified at E8.5, E10.5 and E12.5. Although *Mettl14* knockout embryos could
88 be detected at E6.5 and E7.5, they exhibited largely growth retardation and aberrant morphology (Fig. 2B-2E).
89 Thus, these data suggest that *Mettl14* is indispensable for mouse early development.

90 **Whole transcriptome profiling of E5.5 *Mettl14*^{-/-} embryos**

91 To investigate the molecular consequences of *Mettl14* depletion in mouse early embryogenesis, we
92 isolated mRNA from control and *Mettl14*^{-/-} embryos at E5.5 and performed RNA sequencing. We chose E5.5
93 mouse embryos because the mutant embryos at this stage were undistinguishable in morphology from the
94 normal littermates, therefore minimizing molecular changes ascribed to secondary developmental defects in
95 the absence of METTL14. The RNA-seq data were mapped to the mouse genome (mm9) with Hisat2, which
96 was published in Nature Protocol to mapping data efficiency. A total of 37979006 (91.4%, WT1), 43551393
97 (92.32%, WT2) and 46031008 (92.18%, KO1), 62093886 (94.95%, KO2) mapped reads were obtained and
98 used for downstream bioinformatics analysis for the control and *Mettl14*^{-/-} embryos, respectively. The results
99 showed that with a cutoff of fold change > 2, P<0.01, there were nearly 1060 differentially expressed genes
100 (DEGs) compared with the control group, indicating that the transcriptome signature was significantly disturbed
101 in E5.5 *Mettl14*^{-/-} embryos. Then, replicate Multivariate Analysis of Transcript Splicing (rMATS) software was
102 adopted to analyze the differential alternative splicing events between control and *Mettl14*^{-/-} transcriptomes
103 (Fig.3A). We showed that multiple alternative splicing events were affected in the absence of METTL14, with
104 exon skipping to be the most prevalent one (Fig. 3B), which is consistent with previous reports that m⁶A could

105 regulate biological processes through regulating alternative splicing events (Bartosovic et al., 2017). To identify
106 the affected biological processes that may underlie the developmental failure of *Mettl14*^{-/-} embryo, gene
107 ontology (GO) analysis was performed with the DEGs. The results showed that dysregulated genes were
108 enriched in embryo development pathways such as in utero embryonic development, anterior/posterior pattern
109 specification, trophectodermal cell differentiation, endoderm development, Wnt signaling pathway, Tgfβ
110 receptor signaling pathway and Notch signaling pathway, all of which are differentiation-related events or
111 signaling pathways essential for mouse early development (Fig. 3C). Thus, our data showed that the early
112 embryonic lethality of *Mettl14* mutants might be a result of impaired differentiation after implantation. Genes,
113 reported function in cell differentiation and anterior/posterior pattern specification, were mapped into an
114 interaction network to illustrate regulatory relationships by Cytocape (Fig. 3D). The genes were significantly
115 dysregulated in *Mettl14*^{-/-} embryos at E5.5. Thus, our study showed that *Mettl14*-mediated m6A may play a
116 significant role in early embryo development in mice by regulating the expression and alternative splicing of
117 mRNA.

118 **Depletion of *Mettl14* results in the resistance to differentiation of epiblast *in vivo***

119 GO analysis indicated that the compromised post-implantation development of *Mettl14*^{-/-} embryos might lie in
120 the defects of epiblast differentiation. The conversion of the pluripotent epiblast from a naïve to primed state is
121 an important event essential for mammalian development after implantation. To investigate whether this
122 conversion proceeds normally in the absence of METTL14, we examined the expression of naïve and primed
123 markers in E5.5 normal and *Mettl14*^{-/-} embryos with the RNA-seq data. Notably, the expression level of many
124 naïve markers, including *Nr5a2*, *Klf2*, *Rex1* and *Tfcp2l1* in E5.5 *Mettl14*^{-/-} embryos were higher compared to
125 the control, while the primed markers, such as *Dnmt3b*, *Otx2*, and *Sox3* were largely down-regulated (Fig. 4A).
126 These data suggested that depletion of *Mettl14* led to impaired epiblast maturation from the naïve to primed
127 state *in vivo*. This result was further validated using immunofluorescent staining of the naïve marker NANOG in
128 E6.5 embryos. While NANOG is expressed in a restricted region in the proximal posterior epiblast in normal
129 E6.5 mouse embryos, its expression was expanded to the whole epiblast after *Mettl14* deletion (Fig. 4C). The
130 expression of general pluripotency marker POU5F1 was little affected (Fig. 4D).

131 ***Mettl14* facilitates the conversion from naïve to primed pluripotency**

132 To better resolve the function of *Mettl14* in mouse early embryogenesis, we attempted to derive ESCs from

133 E3.5 blastocysts of *Mettl14*^{+/+} intercrosses for further analysis. *Mettl14*^{-/-} blastocysts were largely normal and
134 could not be morphologically distinguished from the normal counterparts. A total of 35 blastocysts from 4 mice
135 were obtained for ESCs derivation, among which 32 colonies were successfully grown out and 8 of them were
136 *Mettl14*^{-/-}, as determined with genotyping (Fig.5A, S1). Disruption of *Mettl14* was further confirmed by
137 immunofluorescence and Western blot analysis (Fig. 5B, 5C). While WT ESCs exhibited typical dome-shaped
138 morphology, we observed relatively flattened and irregular morphology of *Mettl14*^{-/-} ESCs in 2i/L medium (Fig.
139 5D). *Mettl14* depletion also decreased ESCs proliferation compared to the control (Fig. 5E). However, the key
140 pluripotency regulators like *Pou5f1*, *Nanog* in *Mettl14*^{-/-} ESCs showed comparable protein levels to those in the
141 WT ESCs (Fig. 5F, 5G). Additionally, the activity of alkaline phosphatase (AP), a typical ESCs marker,
142 remained constant in *Mettl14*^{-/-} ESCs (Fig.5H). These data suggest that depletion of *Mettl14* has little effect on
143 ESCs self-renewal.

144 We further tested the ability of *Mettl14*^{-/-} ESCs to convert from naïve pluripotency to the primed state *in vitro*.
145 WT and *Mettl14*^{-/-} ESCs were cultured in primed epiblast like cell (EpiLC) medium containing Fgf2 and Activin A
146 for three days (Brons et al., 2007; Hayashi et al., 2011). Both WT and *Mettl14*^{-/-} ESCs showed a flattened
147 morphology during the pluripotency conversion and down-regulated naïve markers and up-regulated primed
148 markers. However, the naïve pluripotency markers (*Klf2*, *Klf4*) and the primed pluripotency markers (*Dnmt3b*,
149 *Wnt3*) were resistant to down-regulation and up-regulation, respectively, compared to the control (Fig. 5I),
150 indicating impaired pluripotency conversion *in vitro*. It is noticeable that the expression of the naïve marker
151 *Nanog* and the primed marker *Fgf5* were comparable to that in the control, suggesting that the conversion from
152 naïve to primed state was initiated but compromised in the absence of METTL14. Thus, loss of *Mettl14* and the
153 resulting decreased m⁶A level hampers the priming and further differentiation competence of ESCs, which
154 might account for the impaired cell fate commitment of the epiblast *in vivo*.

155

156 DISCUSSION

157 Eukaryotic mRNA posttranscriptional modification is essential for mRNA maturation, including addition of a
158 5' cap, addition of a 3' poly-adenylation tail, and splicing. Recently, attention has been focused on the
159 physiological function of m⁶A (2-5). m⁶A, the most prevalent internal (non-cap) modification present in mRNA,
160 that affects corresponding mRNA stability and translation status, and is involved in multiple biological

161 processes, including regulation of stem cell differentiation and reprogramming (Batista et al., 2014; Geula et al.,
162 2015; Liu et al., 2014), circadian periods (Fustin et al., 2013), cell cycle, splicing, and embryonic development
163 (Horiuchi et al., 2013; Horiuchi et al., 2006; Ping et al., 2014). However, the function of m⁶A in mammalian early
164 embryo development remains largely unclear. In this study, we found that *Mettl14*, and maybe *Mettl14*
165 mediated m⁶A modification was indispensable for mouse post-implantation embryogenesis by regulating the
166 expression of important regulators for conversion of the epiblast from naïve to the primed state.

167 Related studies about m⁶A during post-implantation embryo development mainly relied on embryonic stem
168 cells and embryoid bodies, which, after all, are models in vitro. In a previous study, Shay et al reported that
169 *Mettl3* mutant led to embryonic lethality at E6.5 because of failure to down-regulation of *nanog* mRNA.
170 Confusingly, Wang et al showed that m⁶A methylation inversely correlated with mRNA stability and gene
171 expression enriched in developmental regulators. METTL14, as the core component of the RNA
172 methyltransferase complex, is active and possesses different sets of transcripts compared with METTL3 even
173 though many of their targets overlap. One potential mechanism seems to be the selective regulation of different
174 functions and pathways (Yanan Yue, 2015). Recently, studies have reported that catalysis of the N6
175 -methyl-adenosine mRNA modification m⁶A by a complex containing METTL3 and METTL14 is indispensable
176 for normal spermatogenesis in mice, which showed that Vasa-Cre-mediated ablation of *Mettl3* or *Mettl14* led to
177 a loss of m⁶A and consequent depletion of spermatogonial stem cells (Lin et al., 2017; Xu et al., 2017).
178 However, Str8-Cre-mediated deletion of either *Mettl3* or *Mettl14* in advanced germ cells did not affect normal
179 spermatogenesis, which indicates independence of METTL3 and METTL14 (Lin et al., 2017).

180 In our study, we generated *Mettl14* mutant embryos and found that ablation of *Mettl14* led to abnormal
181 embryo development since E6.5. To further investigate the mechanism underlying this phenotype, RNA
182 sequencing (RNA-Seq) based on paired-end high-throughput sequencing methods was adopted to provide
183 insight into the transcriptome of E5.5. Transcriptome analysis revealed that deletion of *Mettl14* resulted in
184 dysregulation of plenty of gene expression enriched in embryo development pathways such as
185 trophectodermal cell differentiation, endoderm development, Wnt signaling pathway, in utero embryonic
186 development, anterior/posterior pattern specification, transforming growth factor beta receptor signaling
187 pathway and Notch signaling pathway, all of which are differentiation related events or signaling pathways
188 essential for mouse early development. However, the previously reported key pluripotency factors such as
189 Nanog do not make a significant difference.

190 An important question is raised: what is the mechanism responsible for the phenotype caused by *Mettl14*
191 mutation? Whether it is a result of failure to decrease the *Nanog* expression as previously reported in *Mettl3*
192 mutant(Geula et al., 2015) or a result of failure of expression of differentiation-related genes as revealed in our
193 study needs further confirmation. Inconsistent with other naïve markers such as *Klf2*, mRNA level of *Nanog*
194 showed no significant difference compared with the WT group in *Mettl14^{-/-}* embryos. It is possible that other
195 regulator may contribute to epiblast maturation, which needs further investigation. The functional mechanisms
196 of m⁶A and its related regulators in post-transcriptional regulation of epiblast maturation is only starting to be
197 uncovered.

198 **MATERIAL AND METHODS**

199 **Mice**

200 All mouse lines were kept in compliance with the guidelines of the Animal Care and Use Committee of the
201 Institute of Zoology at the Chinese Academy of Sciences. Mice were killed under standard protocols, and all
202 efforts were made to minimize suffering. All mouse strains were maintained in a C57BL/6 background.
203 *Mettl14^{+/-}* female mice were mated with *Mettl14^{+/-}* male mice to generate *Mettl14^{-/-}* embryos. Gestational age of
204 embryos was determined by checking vaginal plugs, with noon of the day of the plug appearance defined as
205 embryonic day (E) E0.5.

206 **Immunohistofluorescent staining and imaging**

207 For immunohistofluorescent staining, the 5 μ m sections of post-implantation embryos were incubated with 5%
208 donkey serum in 0.3% triton X-100 for 1 hr after rehydration and antigen retrieval. Then the sections were
209 incubated with primary antibody overnight at 4°C and then washed in PBS for three times. The membranes
210 were incubated with corresponding F499- or F488-conjugated goat anti-rabbit IgG (1:400, Invitrogen) for 1 hr at
211 room temperature. Finally, images were collected using confocal laser scanning microscopy (Carl Zeiss Inc).

212 **ESCs derivation, culture and conversion of ESCs to EpiLCs**

213 ESCs derivation was performed as previously described with only little modification(Bryja et al., 2006). Briefly,
214 E3.5 blastocysts were obtained and seeded separately on MEF feeders in 3.5 cm culture dishes in KSR ES
215 medium. One week later, the outgrowth of each blastocyst was picked and disaggregated with TypLE Express

216 Enzyme (Gibco), and transferred to 96-well plate in 2i/L medium (N2B27 medium supplemented with 1 μ m
217 PD0325901, 3 μ m CHIR99021 and 1000 units ml⁻¹ LIF). About three days later, clones were disaggregated and
218 transferred to 24-well plates for routine culture. ESCs were routinely maintained on 0.2% gelatin coated dishes
219 in 2i/L medium and propagated at a split ratio of 1:5.

220 For conversion of ESCs to EpiLCs, 1 \times 10⁵ ESCs were seeded in one well of a 12-well plate coated with Matrigel
221 in N2B27 medium containing Activin A (20 ng/ml), bFGF (12 ng/ml), and 1% KSR for three days. Medium was
222 changed every day.

223 **mRNA extraction and quantitative real time-PCR**

224 Total RNA was extracted from testis using TRIzol kit following the manufacturer's instructions. mRNA level of
225 each gene was validated by quantitative real-time PCR (qRT-PCR) analysis (Roche480) according to the
226 manufacturer's instruction. Primer sets used were listed in Table S1.

227 **Western blot analysis**

228 A total of 2X10⁶ ESCs per sample were mixed with 2X SDS sample buffer and boiled for 5 minutes at 100°C for
229 SDS-PAGE. Western blotting was performed as described previously, using the primary antibody dilution
230 anti-METTL14 (ATLAS ANTIBODIES, HPA038002) at 1:1000, anti-Nanog (Abcam, ab62734), anti-Pou5f1
231 (Santa Cruz, sc-5279), anti- β -actin (Zhongshan Golden Bridge Biotechnology) at 1:1000. Secondary
232 antibodies were horseradish peroxidase-linked. Horse-radish peroxidase-linked secondary antibodies
233 (Zhongshan Golden Bridge Biotechnology) were diluted at 1:2000. Protein bands were detected using Thermo
234 Supersignal West Pico chemiluminescent substrate.

235 **Whole transcriptome profiling.**

236 Four E5.5 embryos were subjected to RNA-seq. RNA was isolated from single E5.5 embryo and amplified
237 using SMART-SeqTM v4 UltraTM Low Input RNA Kit (Clontech) , and sequenced by Novogene Corporation.
238 Then we identified the genotype of four embryos based on *Mettl14* qRT-PCR of parts of the returned amplified
239 cDNA. Fortunately, two embryos were identified as *Mettl14*^{-/-}, while the other two embryos expressing *Mettl14*
240 mRNA were classified as control group. Library construction was performed following Illumina manufacturer

241 suggestions. Libraries were sequenced on the Illumina Hiseq PE150.

242 **Statistical analysis**

243 The RNA-seq data were mapped to the mouse genome (mm9) with the software published, and
244 differential expression genes were revealed by using the R package DEseq2. The mapping outcomes were
245 sorted with the software Samtools to obtain a regular processed results; after getting the reads matrix of each
246 group by using Stringtie, differentially expressed genes were screened with the R package (DEseq2). All data
247 presented were collected from at least three independent experiments and analyzed using SPSS (SPSS
248 China). Data were expressed as mean \pm SEM and significance of differences was evaluated with Student's
249 t-test.

250

251 **ACKNOWLEDGEMENT**

252 This study was supported by the National Key R&D Program of China (No 2016YFA0100400;
253 2016YFC1000600) and the National Natural Science Foundation of China (31472055, 31671559), and Youth
254 Innovation Promotion Association CAS (2017114).

255

256 **CONFLICT OF INTEREST**

257 The authors declare no conflict of interest.

258

259 **REFERENCES**

260

261 **Arnold, S. J. and Robertson, E. J.** (2009). Making a commitment: cell lineage allocation and axis patterning in the early
262 mouse embryo. *Nat Rev Mol Cell Biol* **10**, 91-103.

263 **Bartosovic, M., Molaes, H. C., Gregorova, P., Hrossova, D., Kudla, G. and Vanacova, S.** (2017). N6-methyladenosine
264 demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3'-end processing. *Nucleic Acids Res*
265 **45**, 11356-11370.

266 **Batista, P. J., Molinie, B., Wang, J., Qu, K., Zhang, J., Li, L., Bouley, D. M., Lujan, E., Haddad, B., Daneshvar, K., et al.**
267 (2014). m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell stem cell*
268 **15**, 707-719.

- 269 **Brons, I. G., Smithers, L. E., Trotter, M. W., Rugg-Gunn, P., Sun, B., Chuva de Sousa Lopes, S. M., Howlett, S. K.,**
270 **Clarkson, A., Ahrlund-Richter, L., Pedersen, R. A., et al.** (2007). Derivation of pluripotent epiblast stem cells
271 from mammalian embryos. *Nature* **448**, 191-195.
- 272 **Bryja, V., Bonilla, S. and Arenas, E.** (2006). Derivation of mouse embryonic stem cells. *Nat Protoc* **1**, 2082-2087.
- 273 **Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al.** (2013).
274 Multiplex genome engineering using CRISPR/Cas systems. *Science (New York, N.Y.)* **339**, 819-823.
- 275 **Evans, M. J. and Kaufman, M. H.** (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature*
276 **292**, 154-156.
- 277 **Fustin, J. M., Doi, M., Yamaguchi, Y., Hida, H., Nishimura, S., Yoshida, M., Isagawa, T., Morioka, M. S., Kakeya, H.,**
278 **Manabe, I., et al.** (2013). RNA-methylation-dependent RNA processing controls the speed of the circadian
279 clock. *Cell* **155**, 793-806.
- 280 **Geula, S., Moshitch-Moshkovitz, S., Dominissini, D., Mansour, A. A., Kol, N., Salmon-Divon, M., Hershkovitz, V., Peer,**
281 **E., Mor, N., Manor, Y. S., et al.** (2015). Stem cells. m6A mRNA methylation facilitates resolution of naive
282 pluripotency toward differentiation. *Science (New York, N.Y.)* **347**, 1002-1006.
- 283 **Hayashi, K., Ohta, H., Kurimoto, K., Aramaki, S. and Saitou, M.** (2011). Reconstitution of the mouse germ cell
284 specification pathway in culture by pluripotent stem cells. *Cell* **146**, 519-532.
- 285 **Horiuchi, K., Kawamura, T., Iwanari, H., Ohashi, R., Naito, M., Kodama, T. and Hamakubo, T.** (2013). Identification of
286 Wilms' tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. *J Biol Chem*
287 **288**, 33292-33302.
- 288 **Horiuchi, K., Umetani, M., Minami, T., Okayama, H., Takada, S., Yamamoto, M., Aburatani, H., Reid, P. C., Housman, D.**
289 **E., Hamakubo, T., et al.** (2006). Wilms' tumor 1-associating protein regulates G2/M transition through
290 stabilization of cyclin A2 mRNA. *Proceedings of the National Academy of Sciences of the United States of*
291 *America* **103**, 17278-17283.
- 292 **Huang, X., Balmer, S., Yang, F., Fidalgo, M., Li, D., Guallar, D., Hadjantonakis, A. K. and Wang, J.** (2017). Zfp281 is
293 essential for mouse epiblast maturation through transcriptional and epigenetic control of Nodal signaling. *Elife*
294 **6**.
- 295 **Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y. G., et al.** (2011).
296 N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nature chemical*
297 *biology* **7**, 885-887.
- 298 **Kalkan, T., Olova, N., Roode, M., Mulas, C., Lee, H. J., Nett, I., Marks, H., Walker, R., Stunnenberg, H. G., Lilley, K. S., et**
299 **al.** (2017). Tracking the embryonic stem cell transition from ground state pluripotency. *Development* **144**,
300 1221-1234.
- 301 **Lin, Z., Hsu, P. J., Xing, X., Fang, J., Lu, Z., Zou, Q., Zhang, K. J., Zhang, X., Zhou, Y., Zhang, T., et al.** (2017).
302 Mett13-/Mett14-mediated mRNA N(6)-methyladenosine modulates murine spermatogenesis. *Cell Res* **27**,
303 1216-1230.
- 304 **Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al.** (2014). A METTL3-METTL14
305 complex mediates mammalian nuclear RNA N6-adenosine methylation. *Nature chemical biology* **10**, 93-95.
- 306 **Martin, G. R.** (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by
307 teratocarcinoma stem cells. *Proceedings of the National Academy of Sciences of the United States of America*
308 **78**, 7634-7638.
- 309 **Ping, X. L., Sun, B. F., Wang, L., Xiao, W., Yang, X., Wang, W. J., Adhikari, S., Shi, Y., Lv, Y., Chen, Y. S., et al.** (2014).
310 Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. *Cell Res* **24**,
311 177-189.
- 312 **Sibbritt, T., Patel, H. R. and Preiss, T.** (2013). Mapping and significance of the mRNA methylome. *Wiley Interdiscip Rev*

313 *RNA* **4**, 397-422.

314 **Tesar, P. J., Chenoweth, J. G., Brook, F. A., Davies, T. J., Evans, E. P., Mack, D. L., Gardner, R. L. and McKay, R. D.** (2007).
315 New cell lines from mouse epiblast share defining features with human embryonic stem cells. *Nature* **448**,
316 196-199.

317 **Wang, Y., Li, Y., Toth, J. I., Petroski, M. D., Zhang, Z. and Zhao, J. C.** (2014). N6-methyladenosine modification
318 destabilizes developmental regulators in embryonic stem cells. *Nat Cell Biol* **16**, 191-198.

319 **Xu, K., Yang, Y., Feng, G. H., Sun, B. F., Chen, J. Q., Li, Y. F., Chen, Y. S., Zhang, X. X., Wang, C. X., Jiang, L. Y., et al.** (2017).
320 Mett13-mediated m(6)A regulates spermatogonial differentiation and meiosis initiation. *Cell Res* **27**, 1100-1114.

321 **Yanan Yue, J. L. a. C. H.** (2015). RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation.
322 *GENES&DEVELOPMENT*.

323 **Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C. M., Li, C. J., Vagbo, C. B., Shi, Y., Wang, W. L., Song, S. H., et al.**
324 (2013). ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Molecular*
325 *cell* **49**, 18-29.

326

327

328 **Figure legends**

329 Figure 1. Establishment of *Mettl14* knockout mouse model. (A) Scheme of targeting *Mettl14* using the
330 CRISPR/Cas9 system. Two sgRNAs were designed to target the intron 1 and intron 2, respectively, to delete
331 the exon 2 in *Mettl14*. DNA sequence of the wild type and the resulting mutant alleles were shown. (B)
332 Genotyping result of the founder mice. Six *Mettl14*^{-/-} founder mice were obtained.

333 Figure 2. Depletion of *Mettl14* leads to early embryonic lethality. (A) Development of *Mettl14*^{-/-} mice. Embryos
334 from *Mettl14*^{+/-} intercrosses were obtained at multiple stages, and the genotypes were determined using PCR.
335 The numbers of *Mettl14*^{+/+}, *Mettl14*^{+/-} and *Mettl14*^{-/-} embryos at each stage were shown. (B and C) *Mettl14*^{-/-}
336 embryos at E12.5 (B, green arrows) and E10.5 (C) were completely resorbed. (D and E) Histological analysis
337 of control and *Mettl14*^{-/-} embryos at E6.5 and E7.5. Note the growth retardation and malformation of E6.5 and
338 E7.5 *Mettl14*^{-/-} embryos. VE, visceral endoderm; Epi, epiblast; ExE, extra-embryonic ectoderm; PAC,
339 proamniotic cavity; NE, neuroectoderm; AC, amniotic cavity; PS, primitive streak; EC, exocoelomic cavity; EPC,
340 ectoplacental cavity

341 Figure 3. Whole transcriptome analysis of the molecular consequences of *Mettl14* depletion at E5.5. (A) The
342 heat map of differentially expressed genes (Fold change >2, $\square < 0.01$) between E5.5 control and *Mettl14*^{-/-}
343 embryos. (B) Alternative splicing signature in E5.5 *Mettl14*^{-/-} embryos. The rMATS software showed that
344 alternative splicing patterns were disturbed after *Mettl14* depletion, with exon skipping the most profound one.
345 (C) GO analysis of the differentially expressed genes in (A). Development-related events and signaling
346 pathways were overrepresented in the GO terms. (D)
347 The interaction network showing genes involved in anterior/posterior pattern specification and cell differentiati
348 on. The regulatory relationships were produced by Cytoscape.


349 Figure 4. Disruption of *Mettl14* impairs epiblast differentiation *in vivo*. (A) The relative expression of naïve and
350 primed markers in E5.5 control and *Mettl14*^{-/-} embryos measured by RNA-seq. The expression level was
351 represented as the ratio of each gene's FPKM value in control to that in *Mettl14*^{-/-} embryos (general and naïve
352 pluripotency markers), or the ratio of each gene's FPKM value in *Mettl14*^{-/-} to that in control embryos (primed
353 markers). (B, C and D) Immunofluorescent staining of METTL14, NANOG and OCT4 in E6.5 control and
354 *Mettl14*^{-/-} embryos. Note the failure of NANOG downregulation in the absence of METTL14.

355 Figure 5. Depletion of *Mettl14* leads to resistance to conversion from naïve to primed state of mouse embryonic
356 stem cells (ESCs). (A) Scheme showing the derivation of *Mettl14*^{-/-} ESCs. *Mettl14*^{-/-} ESCs at Mendelian ratio.
357 (B and C) Immunofluorescent staining (B) and Western blot (C) analysis of the expression of METTL14 in
358 control and *Mettl14*^{-/-} ESCs. (D) The morphology of control and *Mettl14*^{-/-} ESCs. Note the loss of domed shape
359 of *Mettl14*^{-/-} ESCs. (E) Proliferation of WT and *Mettl14*^{-/-} ESCs. The cumulative population doubling was shown.
360 (F and G) Immunofluorescent staining analysis of the expression of POU5F1 and NANOG in control and
361 *Mettl14*^{-/-} ESCs. (H) Alkaline phosphatase (AP) staining of control and *Mettl14*^{-/-} ESCs. (I) qRT-PCR analysis of
362 the expression of naïve and primed markers in epiblast like cells.

363 Figure S1. Genotyping result of the ES colonies.

364 Table S1. Primer sets used were listed.

A




5' TACATA**AAGTGG**....**GAAAC**ACTGGGCTC 3' (WT)

5' TACATA**CATGTACAC**ACTGGGCTC 3' (Delete exon2)

B

M WT 1# 2# 3# 4# 5# 6# 7# M 8# 9# 10# 11# 12# 13# 14#




A

F2	Mettl14 ^{+/+}	Mettl14 ^{+/-}	Mettl14 ^{-/-}
D0	79	178	0
E12.5	4	7	0
E10.5	1	3	0(6*)
E8.5	5	13	0(4*)
E6.5	3	8	(5*)
E5.5	7	16	8
E3.5	9	18	7


B

F2 embryos E12.5





C



E10.5







D


E6.5 mettl14^{+/+}E6.5 mettl14^{-/-}

E


E7.5 mettl14^{+/+}E7.5 mettl14^{-/-}




A



B



C



D

